NCT05056402View on ClinicalTrials.gov

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,382

Participants

Timeline

Start Date

September 19, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cervical CancerCondylomata Acuminata
Interventions
BIOLOGICAL

3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)

Three doses administered intramuscularly at 0, 1 and 6 month.

BIOLOGICAL

2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)

Two doses administered intramuscularly at 0 and 6 month.

Trial Locations (1)

610041

Sichuan Provincial Centre for Disease Control and Prevention, Chengdu

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER